Hair — follicle biology & the androgen problem

What actually decides this outcome, in order of size

Two independent levers, one measurable enzyme, and a set of deficiencies that imitate the whole condition. Ranked by how much of the outcome each one owns:

1. Whether the pattern is androgenetic at all, because three common deficiencies produce diffuse shedding that looks similar and responds to something else entirely. Low Ferritin with a normal hemoglobin, thyroid disease, and low Zinc, RBC each cause telogen shedding. A Canadian consensus on approach and management is the right framework document for the distinction Landells 2025. Getting this wrong means buying a five-alpha-reductase inhibitor for an iron problem.
2. How much time has already passed, because a miniaturized follicle recovers and a scarred one does not. The whole shelf acts on follicles that still exist. That makes this the rare goal where starting earlier is not a preference, and it is the reason a network meta-analysis comparing the two first-line options is worth reading before the first year is spent Gupta 2022.
3. Your follicular sulfotransferase activity, because it decides whether the first-line topical can work on you at all. Minoxidil is a prodrug converted to minoxidil sulfate in the follicle, an enzymatic assay predicting response has been described Goren 2014, and sulfotransferase activity in the hair follicle has been examined as a prognostic marker Pietrauszka 2022. This is the most useful measure-before-you-buy fact in the whole skin and hair estate.
4. Which enzyme isoform you are inhibiting and for how long, because the two drugs are not interchangeable. Finasteride and dutasteride have been compared for regrowth and reversal of miniaturization Almudimeegh 2024, and their pharmacokinetics differ profoundly: finasteride's are characterized in a classic review Steiner 1996 and dutasteride shows parallel linear and non-linear elimination with a very long terminal phase Gisleskog 1999. A long half-life is a commitment as well as an advantage.
5. What the trade actually is, stated in the labeling rather than in a forum. The prescribing information carries the twelve-month adverse experience table and the postmarketing section Propecia label 2022. That document is the honest starting point for the persistent-side-effect conversation, in both directions.
6. Whether there is a scalp condition underneath, because it worsens shedding independently. Ketoconazole shampoo has long-term use data in androgenic alopecia Pierard-Franchimont 1998, sits within the topical antiandrogen literature Marks 2020, and treats the seborrheic dermatitis that frequently accompanies the problem.

The order to run these in, and what has to be true first

Exclude the mimics, measure the one thing that predicts response, then combine two mechanisms rather than escalating one. The ordering principle is what has to be true first.

1. One requisition before any product. Ferritin, TSH (Thyroid-Stimulating Hormone) with Thyroid Antibodies (TPO + TgAb), Zinc, RBC, Vitamin D (25-Hydroxy) and Complete Blood Count (CBC) with Differential. In women add Total Testosterone with SHBG (Sex Hormone-Binding Globulin) and DHEA-S, because a virilizing pattern is a different investigation. Iron is the one that gets missed most, because hemoglobin is normal while the store is not.
2. Minoxidil first, and ask about the enzyme before assuming failure. It prolongs anagen and works independently of androgens, which is why it is the partner to the drug below rather than an alternative Gupta 2022. If there is no response at six months, the sulfotransferase question is the published explanation Goren 2014 Pietrauszka 2022 rather than a reason to escalate blindly.
3. Finasteride second, as the androgen lever, with the labeling read first. The adverse experience table and postmarketing section are in the prescribing information Propecia label 2022. A topical spray formulation has phase 3 data, which changes the exposure question rather than the mechanism Zhou 2025.
4. Ketoconazole Shampoo alongside, because it is cheap and treats a real co-factor. Long-term use data exists in this indication Pierard-Franchimont 1998 and it belongs to the topical antiandrogen group Marks 2020.
5. Dutasteride only if finasteride has been given a full year and the trade is understood. Superior density results come with a higher side-effect probability Almudimeegh 2024 and an elimination profile with a very long terminal phase Gisleskog 1999, which means a decision to stop takes months to unwind.
6. GHK-Cu (inj/oral), AHK-Cu and Biotinoyl Tripeptide are the growth-signal arm and are a separate mechanism from both of the above. They are cosmetic and topical, they do nothing about androgens, and their evidence is cell and animal work rather than controlled human regrowth data.
7. Saw Palmetto and Pumpkin Seed Oil are the botanical end and should be judged against the pharmaceutical effect size rather than against nothing. Saw palmetto has a dose-ranging randomized trial in a different indication that is worth knowing for calibration Barry 2011: increasing the dose did not produce the effect people expected.
8. RU58841 is the item with the worst evidence-to-enthusiasm ratio on this page. A topical androgen receptor antagonist intended to act only at the follicle is a good theory with no completed human safety program behind it. That is a research chemical, and it is stated as one.

What gets bought for this that cannot move it

The category that fails structurally is the hair vitamin. Biotin, collagen and silica supply substrate to a follicle whose problem is a hormonal signal, and substrate was not the limiting term. The exception proves the rule: correcting a genuinely low iron or zinc reverses the shedding it caused, which is why the requisition comes first Landells 2025. Biotin also interferes with many immunoassays, so a hair supplement can corrupt the thyroid and hormone results you are using to investigate the hair.

The surrogate here is how much hair is in the drain, and it is the worst instrument on the page. Shedding is episodic, seasonal and highly visible; density is what actually changed and it moves slowly. Worse, effective treatment produces a temporary increase in shedding as synchronized follicles re-enter the growth phase, so the first six weeks of a working protocol can look exactly like failure. Standardized photographs at fixed distance and lighting are the read-out the trials used Gupta 2022 Almudimeegh 2024, and they cost nothing.

One measurement error that has clinical consequences. Five-alpha-reductase inhibitors roughly halve PSA (Total + Free + % Free), and the effect on the usefulness of that test has been studied directly Andriole 2011. A man on finasteride or dutasteride whose PSA is read at face value is being reassured by an artifact. Tell whoever orders it that you are taking it.

If the goal underneath is different, so is the page. Patchy circular loss is alopecia areata, an autoimmune process with its own treatment literature Gregoire 2025, and nothing on this page addresses it. Diffuse shedding three months after an illness, a birth or a crash in intake is telogen effluvium and resolves on its own timeline. The systemic version of the androgen question is 5-alpha-reductase, DHT & the hair trade-off. And oral low-dose minoxidil has a safety profile documented across a large multicenter series Vano-Galvan 2021 with published serious complications Trueb 2022, which makes it a prescription conversation rather than an internet one.

How you would know it was working, on a real read-out and a real timescale

This page makes two predictions. Nothing here changes a standardized photograph before six months, because the growth phase takes that long to express a change; and treatment-related shedding in the first six weeks is the expected consequence of follicles re-synchronizing rather than evidence of harm.

• Ferritin at baseline and 12 weeks if it was low. Twelve weeks because the store refills slowly, and the target for hair specifically is higher than the threshold used to define anemia.
• TSH (Thyroid-Stimulating Hormone) with Thyroid Antibodies (TPO + TgAb) and Zinc, RBC once, before concluding this is androgenetic. These are the exclusions Landells 2025. Draw them before starting any biotin-containing product, because biotin interferes with the assays.
• PSA (Total + Free + % Free) at baseline in men over forty, before starting a five-alpha-reductase inhibitor, and interpreted with the drug in mind afterwards. The effect on the test has been quantified Andriole 2011, and a baseline is what makes later values interpretable.
• Total & Free DHT with Total Testosterone at baseline and 12 weeks if you want the mechanism check. This is the pharmacodynamic read-out: scalp effect is not measurable at home, but a serum DHT that has not fallen means the drug is not being absorbed or not being taken Steiner 1996.
• Standardized photographs, same distance, same lighting, same part line, monthly for twelve months. This is the endpoint the trials actually used Almudimeegh 2024 and the only one that survives a bad week in the shower.

What will fool you. Shedding is seasonal, with a well-described autumn peak, so a product started in August will look effective by December. Effective treatment increases shedding first. Haircuts, styling products and lighting change how a photograph reads more than three months of treatment does. Serum DHT reflects systemic inhibition and not scalp tissue concentration, so a normal serum value on a topical is not a failure Zhou 2025. Biotin corrupts the very thyroid and hormone assays used to exclude the mimics. And dutasteride's terminal elimination is long enough that stopping it does not produce a clean washout for months Gisleskog 1999.

Sources read for these sections

• Gupta AK, et al. Relative Efficacy of Minoxidil and the 5-alpha Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis. JAMA Dermatology 2022 · PMID 35107565
• Goren A, et al. Novel enzymatic assay predicts minoxidil response in the treatment of androgenetic alopecia. Dermatologic Therapy 2014 · PMID 24283387
• Pietrauszka K, Bergler-Czop B. Sulfotransferase SULT1A1 activity in hair follicle, a prognostic marker of response to the minoxidil treatment in patients with androgenetic alopecia: a review. Postepy Dermatologii i Alergologii 2022 · PMID 35950120
• Vano-Galvan S, et al. Safety of low-dose oral minoxidil for hair loss: A multicenter study of 1404 patients. Journal of the American Academy of Dermatology 2021 · PMID 33639244
• Trueb RM, et al. Serious complication of low-dose oral minoxidil for hair loss. JAAD Case Reports 2022 · PMID 36425662
• U.S. Food and Drug Administration. PROPECIA (finasteride) tablets, 1 mg — full prescribing information, including the twelve-month adverse experience table and the postmarketing report of persistent sexual dysfunction. DailyMed, U.S. National Library of Medicine; label revised 2022
• Zhou C, et al. Efficacy and safety of topical finasteride spray solution in the treatment of Chinese men with androgenetic alopecia: A phase III, multicenter, randomized, double-blind, placebo-controlled study. Chinese Medical Journal 2025 · PMID 40090937
• Almudimeegh A. Comparison between dutasteride and finasteride in hair regrowth and reversal of miniaturization in male and female androgenetic alopecia: a systematic review.. Dermatol Reports 2024 · PMID 39749123
• Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride.. Clin Pharmacokinet 1996 · PMID 8846625
• Gisleskog PO, Hermann D, Hammarlund-Udenaes M. The pharmacokinetic modelling of GI198745 (dutasteride), a compound with parallel linear and nonlinear elimination.. Br J Clin Pharmacol 1999 · PMID 10073740
• Andriole GL, Bostwick D, Brawley OW. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.. J Urol 2011 · PMID 21074214
• Pierard-Franchimont C. Ketoconazole shampoo: effect of long-term use in androgenic alopecia.. Dermatology 1998 · PMID 9669136
• Marks DH. Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris.. Am J Clin Dermatol 2020 · PMID 31832993
• Landells I. A Canadian Consensus on Androgenetic Alopecia: Approach and Management.. J Cutan Med Surg 2025 · PMID 40986632
• Barry MJ, et al. Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA, 2011 · PMID 21954478
• Gregoire S, et al. Local Corticosteroids for Alopecia Areata: A Narrative Review. Dermatology and Therapy 2025 · PMID 40323545